capecitabine has been researched along with hki 272 in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 8 (53.33) | 2.80 |
| Authors | Studies |
|---|---|
| Awada, A; Bonneterre, J; Germa, C; Geyer, CE; Ito, Y; Kim, SB; Lang, I; Martin, M; Ro, J; Vermette, J; Wang, K | 1 |
| Baselga, J; Cortés, J; Garcia-Saenz, JA; Germa, C; Harb, W; Kiger, C; Kim, SB; Martin, M; Moroose, R; Pluard, T; Saura, C; Wang, K; Xu, B | 1 |
| Ben-Baruch, NE; Bose, R; Ellis, MJ; Kavuri, SM; Ma, CX | 1 |
| Anders, CK; Blackwell, KL; Burns, R; Componeschi, KP; Connolly, RM; Cotter, CM; Cropp, AM; Freedman, RA; Gelman, RS; Ibrahim, N; Jankowitz, RC; Krop, IE; Lin, NU; Marte, JM; Melisko, ME; Moy, B; Moynihan, TJ; Nangia, J; Niravath, P; O'Sullivan, CC; Parsons, HA; Pohlmann, PR; Puhalla, SL; Rimawi, MF; Silvestri, K; Smith, KL; Tung, N; Van Poznak, CH; Winer, EP; Wolff, AC | 1 |
| Hurvitz, SA | 1 |
| Stirrups, R | 1 |
| Bradley, CA | 1 |
| Assaf, JD; Escrivá-de-Romaní, S; Garrigós, L; Oliveira, M; Saura, C | 1 |
| Barcenas, CH; Bartsch, R; Glück, S; Harbeck, N; Jackisch, C; Macedo, G; O'Shaughnessy, J; Palma, JD; Pistilli, B; Rugo, HS; Ruiz-Borrego, M | 1 |
| Isaacs, C; O'Regan, R; O'Shaughnessy, JA | 1 |
| Alarcon, J; Ang, PCS; Bebchuk, J; Bose, R; Brufsky, A; Bryce, R; Chan, N; Chu, SC; Delaloge, S; Fagnani, D; Gradishar, W; Hurvitz, SA; Kalmadi, S; Keyvanjah, K; Kim, SB; Kwong, A; Lee, KS; Moy, B; Oestreicher, N; Oliveira, M; Ow, SGW; Ryvo, L; Saura, C; Silverman, P; Zhang, B | 1 |
| Chilà, G; Galizia, D; Geuna, E; Guarini, V; Montemurro, F | 1 |
| Bachelot, T; Bailleux, C; Darlix, A; Jacot, W | 1 |
| Allen, M; Cunningham, N; Johnston, S; Kipps, E; Lee, KA; McGrath, S; Mohammed, K; Noble, J; Okines, AFC; Parton, M; Ring, A; Shepherd, S; Turner, NC | 1 |
| Dong, Z; Fang, Q; Wang, J; Wu, Y | 1 |
3 review(s) available for capecitabine and hki 272
| Article | Year |
|---|---|
Neratinib plus capecitabine for the treatment of advanced HER2-positive breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Disease Progression; Female; Humans; Quinolines; Receptor, ErbB-2; Treatment Outcome | 2020 |
The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Quality of Life; Quinolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Survival Rate; Treatment Outcome | 2021 |
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Capecitabine; Cranial Irradiation; Disease Progression; Female; Humans; Lapatinib; Life Expectancy; Magnetic Resonance Imaging; Metastasectomy; Middle Aged; Oxazoles; Pyridines; Quinazolines; Quinolines; Radiosurgery; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab | 2021 |
4 trial(s) available for capecitabine and hki 272
| Article | Year |
|---|---|
A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Nausea; Quinazolines; Quinolines; Receptor, ErbB-2; Treatment Outcome; Vomiting | 2013 |
Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.
Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Capecitabine; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Middle Aged; Neoplasm Metastasis; Paresthesia; Quinazolines; Quinolines; Receptor, ErbB-2; Syndrome; Trastuzumab; Treatment Outcome | 2014 |
TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Cohort Studies; Female; Humans; Middle Aged; Progression-Free Survival; Quinolines; Receptor, ErbB-2; Survival Rate | 2019 |
Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Quality of Life; Quinolines; Receptor, ErbB-2 | 2021 |
8 other study(ies) available for capecitabine and hki 272
| Article | Year |
|---|---|
HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Female; Humans; Liver Neoplasms; Mastectomy; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinolines; Receptor, ErbB-2; Retreatment | 2015 |
Neratinib Plus Capecitabine Provides a Glimmer of Hope for a Daunting Disease.
Topics: Brain Neoplasms; Breast Neoplasms; Capecitabine; Humans; Quinolines; Receptor, ErbB-2 | 2019 |
Neratinib and capecitabine for breast cancer brain metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Female; Humans; Quinolines; Receptor, ErbB-2; Treatment Outcome | 2019 |
Brain metastases respond to neratinib plus capecitabine.
Topics: Brain Neoplasms; Breast Neoplasms; Capecitabine; Humans; Quinolines; Receptor, ErbB-2 | 2019 |
Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast Cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Dose-Response Relationship, Drug; Female; Humans; Neoplasm Metastasis; Quinolines; Receptor, ErbB-2 | 2021 |
Neratinib: an option for HER2-positive metastatic breast cancer.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Disease Management; Female; Fulvestrant; Humans; Neoplasm Metastasis; Oxazoles; Pyridines; Quality of Life; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab | 2020 |
Neratinib in advanced HER2-positive breast cancer: experience from the royal Marsden hospital.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Female; Hospitals; Humans; Quinolines; Receptor, ErbB-2; Treatment Outcome | 2022 |
Neratinib plus capecitabine versus lapatinib plus capecitabine as the third-line therapy for HER2-positive metastatic breast cancer in China: a cost-effectiveness analysis.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; China; Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Lapatinib; Quality-Adjusted Life Years; Receptor, ErbB-2 | 2022 |